Abdullajon Odilov

Abdullajon Odilov

Auto-generated profile, based on publicly available information

Abdullajon Odilov

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, P. R. China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
YHYi-Fei He
Yi-Fei He
YLYin Liu
Yin Liu
JYJing-Hua Yu
Jing-Hua Yu
HCHuan Cheng
Huan Cheng
AOAbdullajon Odilov
Abdullajon Odilov
XDXingxing Diao
Xingxing Diao
TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [14C]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 μCi) of [14C]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (Tmax) of 0.667 h and a half-life (t1/2) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collected 216 h after administration, accounting for 95.21% of the dose (46.61% in urine and 48.60% in feces). TPN171 underwent extensive metabolism in humans. Twenty-two metabolites were detected in human plasma, urine, and feces using a radioactive detector combined with a high-resolution mass spectrometer. According to radiochromatograms, a glucuronide metabolite of O-dealkylated TPN171 exceeded 10% of the total drug-related components in human plasma. However, according to the Food and Drug Administration (FDA) guidelines, no further tests are needed to evaluate the safety of this metabolite because it is a phase II metabolite, but the compound is still worthy of attention. The main metabolic biotransformation of TPN171 was mono-oxidation (hydroxylation and N-oxidation), dehydrogenation, N-dealkylation, O-dealkylation, amide hydrolysis, glucuronidation, and acetylation. Cytochrome P450 3A4 (CYP3A4) mainly catalyzed the formation of metabolites, and CYP2E1 and CYP2D6 were involved in the oxidative metabolism of TPN171 to a lesser extent. According to the incubation data, M1 was mainly metabolized to M1G by UDP-glucuronosyltransferase 1A9 (UGT1A9), followed by UGT1A7 and UGT1A10.

21 February 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
EBEMMANUEL MINTAH MINTAH BONKU
EMMANUEL MINTAH MINTAH BONKU
HQHongjian Qin
Hongjian Qin
AOAbdullajon Odilov
Abdullajon Odilov
SASafomuddin Abduahadi
Safomuddin Abduahadi
SGSamuel Desta Guma
Samuel Desta Guma
JSJingshan Shen
Jingshan Shen
A ligand-free copper-catalyzed cyclization method is shown for synthesizing benzimidazoles and optimized process of benzimidazoles from cheap o-bromoarylamine and nitriles.

15 September 2023 in Organic Process Research & Development
Verified
Journal Article
Closed access
EBEMMANUEL MINTAH MINTAH BONKU
EMMANUEL MINTAH MINTAH BONKU
HQHongjian Qin
Hongjian Qin
AOAbdullajon Odilov
Abdullajon Odilov
FYFeipu Yang
Feipu Yang
XXXinglong Xing
Xinglong Xing
JSJingshan Shen
Jingshan Shen

6 November 2023 in Organic Process Research & Development
Verified
Journal Article
Closed access
HQHongjian Qin
Hongjian Qin
EBEMMANUEL MINTAH MINTAH BONKU
EMMANUEL MINTAH MINTAH BONKU
AOAbdullajon Odilov
Abdullajon Odilov
MWMingjun Wu
Mingjun Wu
YLYongjian Liu
Yongjian Liu
Haji Akber AisaHaji Akber Aisa
Haji Akber Aisa

13 October 2023 in Tetrahedron
Verified
Journal Article
Closed access
AOAbdullajon Odilov
Abdullajon Odilov
HQHongjian Qin
Hongjian Qin
EBEmmanuel Mintah Bonku
Emmanuel Mintah Bonku
FZFuqiang Zhu
Fuqiang Zhu
FYFeipu Yang
Feipu Yang
JSJingshan Shen
Jingshan Shen

19 September 2024 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
EBEMMANUEL MINTAH MINTAH BONKU
EMMANUEL MINTAH MINTAH BONKU
HQHongjian Qin
Hongjian Qin
AOAbdullajon Odilov
Abdullajon Odilov
SASafomuddin Abduahadi
Safomuddin Abduahadi
SGSamuel Desta Guma
Samuel Desta Guma
JSJingshan Shen
Jingshan Shen
Synthesis approaches for tecovirimat API, highlighting pros and cons, summarizing processes for key intermediates, including cycloheptatriene, and evaluating feasibility, efficiency, and environmental sustainability.